BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28055299)

  • 1. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.
    Dimasi N; Fleming R; Sachsenmeier KF; Bezabeh B; Hay C; Wu J; Sult E; Rajan S; Zhuang L; Cariuk P; Buchanan A; Bowen MA; Wu H; Gao C
    MAbs; 2017 Apr; 9(3):438-454. PubMed ID: 28055299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.
    Sharkey B; Pudi S; Wallace Moyer I; Zhong L; Prinz B; Baruah H; Lynaugh H; Kumar S; Wittrup KD; Nett JH
    MAbs; 2017; 9(2):257-268. PubMed ID: 27937066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.
    Han L; Chen J; Ding K; Zong H; Xie Y; Jiang H; Zhang B; Lu H; Yin W; Gilly J; Zhu J
    Sci Rep; 2017 Aug; 7(1):8360. PubMed ID: 28827777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving target cell specificity using a novel monovalent bispecific IgG design.
    Mazor Y; Oganesyan V; Yang C; Hansen A; Wang J; Liu H; Sachsenmeier K; Carlson M; Gadre DV; Borrok MJ; Yu XQ; Dall'Acqua W; Wu H; Chowdhury PS
    MAbs; 2015; 7(2):377-89. PubMed ID: 25621507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing assembly and production of native bispecific antibodies by codon de-optimization.
    Magistrelli G; Poitevin Y; Schlosser F; Pontini G; Malinge P; Josserand S; Corbier M; Fischer N
    MAbs; 2017; 9(2):231-239. PubMed ID: 28001485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.
    Dillon M; Yin Y; Zhou J; McCarty L; Ellerman D; Slaga D; Junttila TT; Han G; Sandoval W; Ovacik MA; Lin K; Hu Z; Shen A; Corn JE; Spiess C; Carter PJ
    MAbs; 2017; 9(2):213-230. PubMed ID: 27929752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.
    Wranik BJ; Christensen EL; Schaefer G; Jackman JK; Vendel AC; Eaton D
    J Biol Chem; 2012 Dec; 287(52):43331-9. PubMed ID: 23118228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new approach to produce IgG
    Zhao C; Zhang W; Gong G; Xie L; Wang MW; Hu Y
    Sci Rep; 2021 Sep; 11(1):18630. PubMed ID: 34545109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
    Schaefer W; Regula JT; Bähner M; Schanzer J; Croasdale R; Dürr H; Gassner C; Georges G; Kettenberger H; Imhof-Jung S; Schwaiger M; Stubenrauch KG; Sustmann C; Thomas M; Scheuer W; Klein C
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11187-92. PubMed ID: 21690412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
    Tustian AD; Endicott C; Adams B; Mattila J; Bak H
    MAbs; 2016; 8(4):828-38. PubMed ID: 26963837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of bispecific antibodies: diabodies and tandem scFv.
    Hornig N; Färber-Schwarz A
    Methods Mol Biol; 2012; 907():713-27. PubMed ID: 22907382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.